|
|
Article: Population-based laboratory surveillance for AmpC [beta]-lactamase-producing Escherichia coli, Calgary.(RESEARCH)(ampicillin)(Clinical report)
- Article from:
- Emerging Infectious Diseases
- Article date:
- March 1, 2007
- Author:
CopyrightCOPYRIGHT 2007 U.S. National Center for Infectious Diseases. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
In the Calgary Health Region during 2000-2003, prospective, active, population-based laboratory surveillance for all cefoxitin-resistant Escherichia coli isolates was performed. Isolates were screened with an inhibitor-based disk test, and plasmid-mediated types were identified by multiplex PCR with sequencing. A total of 369 AmpC [beta]-lactamase-producing E. coil isolates were identified; annual incidence rates were 1.7, 4.3, 11.2, and 15 per 100,000 residents for each year, respectively. AmpC [beta]-lactamase-producing E. coli was 5x more likely to be isolated from female than male patients across all age groups except
**********
Organisms that produce ...